Related Experiment Video
Updated: Jun 16, 2026
09:39
Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
Published on: July 29, 2016
Current biomarker development in myotonic dystrophies
Malin Larsen1, Daniel H Mendelsohn1, Felix Kleefeld2,3,4
1Department of Neurology, Friedrich-Baur-Institute, LMU Clinics, Munich, Germany.
Journal of Neurology
|June 14, 2026
Summary
Myotonic dystrophies (DM) require better biomarkers for diagnosis and treatment monitoring. Current research explores imaging, muscle, and liquid biopsy approaches, with a focus on minimally invasive methods for improved patient care.
Area of Science:
- Neurology
- Genetics
- Biomarker Research
Background:
- Myotonic dystrophies (DM) are genetic disorders causing muscle weakness and multisystemic issues.
- Current management is symptomatic, leading to diagnostic delays due to clinical variability.
- Emerging therapies necessitate reliable biomarkers for efficacy assessment.
Purpose of the Study:
- To review current biomarker research for myotonic dystrophies (DM).
- To identify challenges and future directions in biomarker development for DM1 and DM2.
Main Methods:
- Review of imaging-based, muscle-derived, and soluble liquid biopsy biomarker research.
- Analysis of alternative splicing pathology markers.
- Assessment of minimally invasive biomarker approaches.
Main Results:
- Established DM biomarkers are limited, with research favoring DM1.
- Alternative splicing markers show promise but often require invasive sampling.
- Minimally invasive soluble markers like microRNAs show potential but need further validation.
Conclusions:
- Reliable biomarkers are crucial for advancing DM diagnosis, prognosis, and therapy.
- Further research is needed to validate existing markers and discover new ones, especially for DM2.
- Development of minimally invasive and disease-specific biomarkers is a key future direction.
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...